US Stock MarketDetailed Quotes

ELVN Enliven Therapeutics

Watchlist
  • 19.920
  • +0.300+1.53%
Close Mar 4 16:00 ET
  • 19.310
  • -0.610-3.06%
Pre 04:17 ET
973.27MMarket Cap-11.05P/E (TTM)

About Enliven Therapeutics Company

Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.

Company Profile

SymbolELVN
Company NameEnliven Therapeutics
Listing DateMar 12, 2020
Founded2019
CEOMr. Sam Kintz, M.B.A.
MarketNASDAQ
Employees46
Fiscal Year Ends12-31
Address6200 Lookout Road
CityBoulder
ProvinceColorado
CountryUnited States of America
Zip Code80301
Phone1-720-647-8519

Company Executives

  • Name
  • Position
  • Salary
  • Sam Kintz, M.B.A.
  • President, Chief Executive Officer and Director
  • 8.28M
  • Dr. Anish Patel, Pharm.D.
  • Chief Operating Officer
  • --
  • Benjamin Hohl
  • Head of Corporate Development, Chief Financial Officer and Principal Accounting Officer
  • --
  • Dr. Helen Collins, M.D.
  • Chief Medical Officer
  • 4.06M
  • Dr. Richard Heyman, PhD
  • Chairman of the Board
  • 664.11K
  • Dr. Rahul D. Ballal, PhD
  • Director
  • 1.87M
  • Dr. Lori Anne Kunkel, M.D.
  • Director
  • --
  • Rishi Gupta, J.D.
  • Independent Director
  • 538.26K
  • Dr. Andrew Phillips, PhD
  • Independent Director
  • 542.95K
  • Jacob Bauer, M.B.A.
  • Independent Director
  • 551.21K
  • Dr. Mika Derynck, M.D.
  • Independent Director
  • 541.48K

Trending Stocks

Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.